Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ETON
ETON logo

ETON Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Eton Pharmaceuticals Inc (ETON) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
37.740
1 Day change
-0.74%
52 Week Range
38.620
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ETON is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong momentum and bullish moving averages, but it is already overbought, has no recent news catalyst, no supportive insider or hedge fund accumulation trend, and option sentiment is mixed rather than strongly bullish. With no Intellectia buy signal and with short-term pattern analysis pointing to downside over the next day, week, and month, the better call is to wait rather than buy at this level.

Technical Analysis

ETON is in a clear uptrend technically: SMA_5 > SMA_20 > SMA_200 and MACD histogram is positive and expanding, which supports bullish momentum. However, RSI_6 at 85.37 signals the stock is significantly overbought, making the current price less attractive for a fresh long-term entry. Price is trading above the pivot at 34.81 and near resistance at 37.31 to 38.855, so upside from here may be limited in the near term. The pattern-based trend signal also suggests weakness ahead, with estimated moves of -0.99% next day, -2.25% next week, and -2.82% next month.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data shows open interest put-call ratio above 1.0, which leans mildly bearish on positioning, while the option volume put-call ratio of 0.06 is heavily call-skewed intraday, suggesting short-term bullish speculation. Total option activity today is very low versus average volume, so the signal is not strong enough to override the price-overbought condition. Implied volatility is elevated at 68.68 with IV rank/percentile both low-moderate, indicating options are not especially cheap or unusually stretched relative to history.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • ["H.C. Wainwright raised the price target to $57 from $52 and kept a Buy rating.", "The analyst cited increased fiscal 2026 revenue guidance and confidence in the growth strategy.", "Technical trend remains bullish with MACD positive and rising and moving averages aligned upward."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "RSI_6 at 85.37 indicates the stock is overbought.", "Open interest put-call ratio of 1.06 suggests positioning is not purely bullish.", "No significant hedge fund or insider buying trend.", "No recent congress trading data.", "Pattern analysis points to negative expected returns over the next day, week, and month."]

Financial Performance

No latest-quarter financial snapshot was provided due to data error, so there is no reliable quarter-by-quarter revenue or earnings breakdown to assess. The only available fundamental clue is the analyst comment referencing increased fiscal 2026 revenue guidance, which implies improving growth expectations, but there is no current-quarter financial detail to confirm execution quality.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is positive and improving: H.C. Wainwright increased its price target to $57 from $52 and reiterated Buy on 2026-05-15, citing stronger fiscal 2026 revenue guidance and confidence in the growth plan. Wall Street pros appear constructive on the company’s long-term growth story, but the current setup is less attractive because the stock is extended technically and lacks fresh catalysts. Overall pros view: bullish on growth trajectory; cons view: valuation/entry timing looks poor after the run-up.

Wall Street analysts forecast ETON stock price to fall
3 Analyst Rating
Wall Street analysts forecast ETON stock price to fall
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.020
sliders
Low
26
Averages
30
High
35
Current: 38.020
sliders
Low
26
Averages
30
High
35
H.C. Wainwright
Buy
maintain
$52 -> $57
AI Analysis
2026-05-15
Reason
H.C. Wainwright
Price Target
$52 -> $57
AI Analysis
2026-05-15
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Eton Pharmaceuticals to $57 from $52 and keeps a Buy rating on the shares. The firm cites the company's increased fiscal 2026 revenue guidance and confidence in its growth strategy for the target bump. Given Eton's execution to date, its stated long-term goals could be achievable, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$26 -> $31
2026-03-20
Reason
B. Riley
Price Target
$26 -> $31
2026-03-20
maintain
Buy
Reason
B. Riley raised the firm's price target on Eton Pharmaceuticals to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced revenue visibility with FY26 guidance above $110M and more than 30% adjusted EBITDA margin, alongside long-term targets of a $200M run-rate exiting 4Q27, 50% margins by 2028, and $500M revenue by 2030, reinforcing a multi-year growth trajectory, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ETON
Unlock Now

People Also Watch